3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
2
Withdrawn
1
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Mesothelioma, Malignant
1
Leukemia, Myeloid, Acute
1
Head and Neck Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Anus Neoplasms
1
Interventions
Radiotherapy
5
Gemcitabine
4
Cyclophosphamide
4
pazopanib
3
Docetaxel
3
Biopsy
3
pembrolizumab
2
olaparib
2
liposomal doxorubicin
2
Vincristine
2
Trastuzumab
2
Trabectedin
2
Temozolomide
2
Taxes
2
Surgical Procedures, Operative
2
Specimen Handling
2
Proton Therapy
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Ifosfamide
2
Filgrastim
2
Etoposide
2
Drug Therapy
2
Doxorubicin
2
Celecoxib
2
Carboplatin
2
Ascorbic Acid
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
trastuzumab biosimilar HLX02
1
tozuleristide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Sarcoma
×
tislelizumab
×
Clear all
NCT05582031
2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2
Withdrawn